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Measuring ROl:
Is It Worth It?
In lean times, healthcare
marketing struggles to prove
its value.
Interview conducted by Richard K. Thomas
R eturn on investment (ROl) for healthcare marketingis a hot topic among healthcare professionals. It hasbeen discussed oif and on in the past, but recentfinancial developments in healthcare have brought
II [o ihe forefront. Today, because of financial pressures, all
operational efforts (including marketing) are under intense
scrutiny, making the bottom line more important than ever.
For many in healthcare, there's a lack of understandmg—
or sometimes all-out confusion—concerning the concept of
ROl, Its not a concept that most health professionals are com-
fortable with, and even those who are often don~t have a clue
as to how to measure marketing ROl—or even know whether
they should try. The discussion presented here attempts to
address the ROl concept—what it is, how its measured, and
where it applies and doesn't apply The panel of experts we've
assembled tackies this thorny issue by offering a wide range
of perspectives on healthcare marketing and diverse views on
the concept of measuring healthcare marketing ROl,
MHS: What are we really talking about when we say "return
on investment" for healthcare marketing activities?
DM: ln simple accountmg terms, ROl is a financial meas-
ure that looks at the percentage return on the use of specific
assets (usually, but not always, money). Two key "formulas"
measure ROl at the organizational level and at the specific
effort level. At the organizational level, ROl is the net income
divided by owners equity At the specific effort level, ROl is
the revenue traceable to the marketing effort divided by the
investment made.
The first definition is the traditional accounting approach.
This definition must be simplified because healthcare organi-
zations tHCOs) typically don't have the systems m place for
more complex measurement of ROL
I' I 'What marketing ROl is depends on the organization
and, to a great extent, the sophistication of senior manage-
ment. For some institutions, a true ROl means the dollars
they're spendmg on marketing are generating some multiple
of dollars in gross revenue. Or at the least they want to see
ROl m terms of patient volume,
^ ! Defining marketing ROl is tough in any industry and
IS particularly a challenge in healthcare, ideally, one would
like to be able to correlate marketing expenditures with the
sales resulting from those expenditures. But there are too
many other vanables for this simple approach to work. One
would also like to be able to think in terms of time-defined
results but, again, this is not easy to do for a lot of healthcare
marketing initiatives. Much of the use of health services is
inelastic and, in many other cases, the consumer has limited
choice, resulting in a need for a different concept of ROl,
CM: At Roska Direct, ROl is very important to us because
we're direct marketers, and our credibility depends on our
being able to measure the results of our promotions. We got
mvolved in the pharmaceutical industry using direct-to-
patient relationship marketing to increase patient compliance
and persistency on long-term medications almost 12 years ago
when direct-to-consumer marketing (DTC) was not yet wide-
spread. As direct marketers we saw an opportunity to increase
the lifetime value of a "customer" for the pharma companies
simply by getting patients to stay on their medications longer.
So we're really looking to quantify the income generated by
these incremental prescriptions-measuring the number of
refills a patient gets above and beyond the normal compliance
period, and comparing the income from those against the cost
of the communications that we did to stimulate that income.
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of patient acquisition, conducting programs to identify
prospective patients, get ihem to discuss our product with
their physician, and provide an incentive for ihe first.
MHS: Are there fairly standardized methods of measuring
ROI, at least in other industries if not healthcare?
DM: ROI measurement is common in other industries, hut
most of these lend themselves more easily to measuring the
bottom-line contribution of marketing. These traditional
approaches have limited application in healthcare. And actual-
ly in healthcare many CEOs are really talkmg about ROE
(return on expenditures) when they say ROI.
\M For most HCOs, management doesn't hold marketers
to a financial bottom line in marketing, and most ol the meas-
ures for ROI are softer measures like goodwill, awareness, or
PR coverage. True, HCOs are beginning to look more closely
at ROI measurement techniques, but they have a long way to
go in adopting techniques from other industries.
ST: Because of the unique characteristics of healthcare, I
would see ROI in terms of its impact on more global dimen-
sions such as brand awareness. If marketing efforts raise
brand awareness (and brand equity) by a certain number of
percentage points, then you have a rough indicator of ROI.
CM: Generally, we try to apply the standard direct market-
ing methods of calculating return on investment—that is,
comparing the cost to acquire a new customer against the
value of that customer over a specific period of time. It's com-
monly used by catalogers, book and record clubs, financial
ser\'ice marketers, and other direct marketing organizations.
We have also engaged in programs where we've held out a
region as a control and kept our promotions out of that region
so we could measure the incremental sales changes in the pro-
motion regions vs. the non-promotion regions. This isn't per-
fect, but it allows you to see if the promotions are moving the
sales needle.
MHS: Why is the measurement of marketing ROI more of a
challenge in healthcare than in other industries?
DM: Other measurements (market share, brand position,
preference, etc.) are likely to have more validity (and measur-
ability) in the long run than does ROI. Among other factors is
the time delay in the appearance of marketing results and the
fact that the use of health services is not likely to be triggered
by marketing, but will be situational. Eurther, many efforts
toward marketing health ser\'ices simply don't have a measur-
able return. Ultimately, a variety of factors are likely to mflu-
ence the use of health ser\'ices.
CM: A number of things make ROI measurement a chal-
lenge in healthcare. First, the actual sale of the product is
removed from the pharmaceutical company. It takes place at
the pharmacy alter a physician has specified the product.
That's why we developed different transaction-related incen-
tives to track sales. Second, many of the pharmaceutical mar-
keters don't track the average length ol time a patient stays on
their product. This information usually has to come from
aggregate data supplied by a pharmacy chain or pharmacy
benefits manager (prescription plan),
ST: A major issue is the lack of access to the necessary
data—on both the expense and revenue sides. HCOs typically
can't accurately isolate the costs associated with a marketing
initiative from other factors. Nor can they precisely determine
how much of incremental revenue can be attributed to a mar-
keting initiative. How can the role of referrals be accounted
for, and how does the organization account for revenue gener-
ated m other areas besides the targeted service line (e.g., inpa-
tient admissions resulting from an urgent care center cam-
paign)? Even if adequate data systems were in place, there's
the ethical issue of segmenting patients based on various traits
and subsequently marketing (or de-marketing) to them.
Dl- There are several reasons why the ROI measurement is
a challenge in healthcare. Eirst, marketing is a fairly young
discipline in healthcare (at least in provider-related healthcare
services). Second, administrators and senior management
don't know enough about marketing to ask the right ques-
tions. Third, many healthcare marketers don't possess the tal-
ent (or maybe the interest) for trymg to measure ROI.
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MHS: Are there inherent barriers in healthcare that prevent
effective measurement of ROl?
Mt As with any business the purpose of marketing is to
speed up the purchase decision. But healthcare isn't usually
an impulse buy So speeding up consumer decision making is
difficult if not impossible (unless it's an optional service like
plastic surgery). Marketing is about dominating share of
mind, it's also something that takes a long time and many
repeated impressions to be successful. The lead time for a
healthcare decision can be months or years, so the immediate
results are often hard to measure. And healthcare is a compli-
cated purchase with lots of factors involved; rarely is market-
ing by itself the sole reason someone buys a health service.
Healthcare also is not very consumer-driven when you factor
in physicians and managed care (and much of healthcare
marketing is consumer marketing). Internal tracking and
accounting systems in most HCOs are terrible and don't pro-
vide the right marketmg mformation,
1>'\!, HCOs typically don't have financial accounting sys-
tems in place to provide accurate pricing, cost, and margin
information. Further, the way overhead is allocated in health-
care makes ii difficult to isolate the effect of an activity like
send you a special promotion if you haven't used your
account in six months, the pharma company can't know that
a specific patient hasn't had his prescription renewed. The
pharmacy chains have compliance programs designed to stim-
ulate refills from patients who are late getting their medication
renewed. These programs usually aren't disease-specific, pro-
viding information like, "Here's why you need to have your
cholesterol medication renewed,"
MHS\ What types of marketing activities in healthcare lend
themselves best to tracking ROI?
DM: Most healthcare activities don't readily lend them-
selves to this approach but, at the same time, with proper sys-
tems in place many activities can be tracked for ROI. There
are some ser\'ices (e.g., LASIK eye surgery and some other
elective procedures) where ROI measurement makes more
sense. Also, marketing efforts that involve a single marketing
activity for a specific service have a better chance of being
measurable. But even with something as straightforward as
childbirth, you're looking at up to nine months before you
can see any results. Most healthcare marketing can't be used
to drive short-term volume increases, so marketers must focus
on longer-term metrics like awareness levels.
"HCOs are beginning to look more closely at ROI measurement techniques, but
they have a long way to go in adopting techniques
from other industries". -
marketing. Fven where systems are in place, healthcare mar-
keters seldom have the knowledge of financial measurement
and trackmg. In addition, healthcare tracking systems aren't
often geared toward measuring changes in volume or specific
usage tied to marketing efforts,
S I A major assumption of RO! measurement is that it's
possible to control most of the variance in the equation. But,
if you have anything in healthcare, you have unexplained
variance. Thus, ROI at the service or product level is difficult
to measure. Further, the "miscellaneous" item in most health-
care budgets is so large as to limit the usefulness of the finan-
cial statements in measuring ROl. Another issue has to do
with adjusting for patients that would have used the service
anyway. If the patient's health plan dictates the use of a facility
or service, it's not appropriate to attribute that patient to the
marketing initiative,
CM: The high importance of protecting patient privacy
prevents you from looking at the profit from a particular
patient, the way a cataloger or even a grocery store can. So,
while the department store where you have a credit card can
CM: Direct-to-patient relationship marketing is really the
most measurable form of marketing activity because we can
tell how many patients received our product as a result of the
promotion, and we can communicate with them directly to
help them understand why it's important to take their medica-
tion. We can put mechanisms in place to measure how long
they take the product. Sometimes we use patient surveys to
lind out it they're still taking the product and how frequently
they take it. We have also partnered with pharmacy chains to
track refills among patients who are enrolled in compliance
programs vs, those who are not, and report the data to us in
aggregate,
A few activities are more suitable than others. These
include sales efforts, direct-response campaigns (like physi-
cian referral or newcomers packets), product line marketing
and advertising, and call center operations. In these situa-
tions, it's somewhat more feasible to hnk results to marketing
expenditures,
•^  i Healthcare marketers are much better off looking at
things they can more easily track and measure, like the num-
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ber of new enrollees brought into a
managed care plan as a result of mar-
keting. Global indicators seem much
more suitable than measures of ROI for
specific services.
MHS: Do some new marketing tech-
niques lend themselves better to ROI
measurement than traditional marketing
approaches?
I )f . Some of the new CRM pro-
grams are doing a good job of building
in tracking measures. Certainly the
growth of call centers and the Internet
is supporting better measurement.
Where we see organizations struggle
is when they are trying to find one for-
mula or one method for accounting for
their entire marketing program (which
may consist of dozens or even hun-
dreds of different strategies and tactics).
The better way to begin measuring ROI
is to break everything down into specif-
ic product lines or even specific activi-
ties and measure each as best as possi-
ble. Some will be financially driven,
others won't. Then take the sum of
everything and use it to look at the
effectiveness of marketing overall. It's a
more complicated and tedious process
(which is why few marketers do it), but
it generates much better information
lor the organization.
DM: Some approaches such as CRM
and DTC marketing lend themselves
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better to measurement than more tradi-
tional marketing techniques. Some of
the Web-based marketing being imple-
mented today may also lend itself to
better measurement with its built-in
tracking capabilities.
^ I CRM appears to have a lot of
potential for ROI measurement. CRM is
all about understanding customers, and
that should lead to better ability to
track behavior and link it to marketing
investment. Still, we don't have ade-
quate systems in place, and healthcare
faces the segmentation issue mentioned
earlier. Limitations on data sharing,
which are likely to become more strin-
gent, also are a consideration.
CM: Relationship marketing to
patients and non-personal promotion to
physicians are emerging as areas where
you can directly quantify the effects of
promotional efforts. Traditionally, phar-
maceutical companies market to doc-
tors through sales representatives. But
representatives can't see every doctor.
We have worked with individual physi-
cian prescribing data to segment doc-
tors who aren't called on by representa-
tives. We look at the volume of pre-
scriptions that doctors are writing-^say
for high blood pressure—and how
many of those prescriptions are for our
product. We can then customize mes-
sages to the doctors who represent the
greatest potential for growing our mar-
ket share—those who prescribe a lot of
drugs in the class but not a lot ot our
product. We can customize a different
message for the doctors who write a lot
of drugs in the class and a lot lor our
product. We can then look at the pre-
scribing behavior of those same physi-
cians who received the promotion in
subsequent periods to determine if
we've increased the number of prescrip-
tions written.
MHS: Do some types of HCOs lend
themselves better to ROI measurement
than others?
My experience suggests that sin-
gle-purpose organizations and organiza-
tions that can isolate activities are much
more appropriate for such measure-
ment. These include specialty facilities
like rehab centers and drug and alcohol
treatment facilities, urgent care/walk-m
care centers, referral/health information
services, birthing centers, and specialty
services like ophthalmology, orthopedic
centers, plastic surgery. Insurance and
related services and products also
appear to be good candidates.
DM: The best candidates appear to
be HCOs with a single focus—like
LASIK surgery, occupational health,
psychiatric hospitals—or organizations
that offer unusual services—like sleep
labs. Its easier to argue that no one
comes to the sleep lab because they
were at the hospital for some other rea-
son and thought they would have a
sleep pattern evaluation. Ultimately the
type of service organization may be less
important than its support systems.
Organizations with good information
systems make the best candidates
regardless of the type of service provid-
ed. Eor this reason, doctors" offices are
typically the worst candidates.
^ ! At first blush, one would think
smaller, less complex organizations
would be belter candidates for measur-
ing ROI. But this is only true to a point
(with physician offices probably being
the counterexample). Perhaps it's not so
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much the type of organization but its
attributes that make the difference.
Organizations that have adequate data
systems in place clearly are better can-
didates. Thus, organizations associated
with managed care plans are likely to
have better data systems and a better
chance of measuring ROI. Also, those
organizations where the leadership and
key clinicians buy into the notion of
ROI measurement should be candi-
dates. If this isn't considered important
by key indi\iduals. then it's not likely
to happen.
CM: The ability to work with phar-
macy benefit managers and managed
care organization (MCO) claims data-
bases provides a great opportunity to
look at the effects of communicating
ilirectly with patients about how to
manage their condition and create bet-
ler outcomes. Patients who understand
how to take care ol themselves are
healthier and end up costing the MCO
less money This is particularly true in
areas like diabetes and cardiovascular
disease where the cost of hospitaliza-
tion can be very expensive to a health
plan. Educating the patient about tak-
ing their medication and leading a
healthy lifestyle creates a win-win-win
situation—for the patient, the pharma-
ceutical company, and the healih plan.
MHS: How can ROI be applied to
long-term objectives such as brand
building and image enhancement?
Good marketing ROI not only
attempts to account for direct revenue
from specific marketing efforts, but also
incorporates the psychology of market-
ing that drives consumer behavior over
a period of time. In other words, we
know from almost every industry that
marketing—and specifically advertis-
ing—drives purchases. And that mar-
keting starts at the point of awareness
and continues through to brand differ-
entiation, brand loyalty, etc. What's
always been the most difficult to meas-
ure is how much and when that mar-
keting is most effective. Marketing effi-
ciency is more difficult to measure than
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effectiveness. We know marketing is
effective. What we really want to know
is how to be more efficient with our
marketing spending so we waste less
and get more for our money.
DM; This is really the place where
the concept can be best applied and
measured. Few bealthcare marketing
initiatives drive short-term gains, but
are more long-term in their orientation.
The benefits of marketing should be
measured in terms of how many con-
sumers demonstrate top-of-mind
awareness or how many legislators are
willing to support the organization on
important issues.
CM: We have a saying in our mar-
keting agency that sales equals aware-
ness. If we make someone aware of
your product, that doesn't mean they're
going to buy it. But if we can get some-
one to buy it, we can guarantee they're
aware of it. Thus, marketing efforts that
encourage consumers to try a product
or service should be given prece-
dence—then, the awareness building
can proceed. Remember, we're looking
beyond short-term gain to the lifetime
value of the customer.
s I: As I noted above, these types of
outcomes should be what are used to
measure ROI in healthcare. There are
just too few situations where micro-
level measurement makes sense. But
brand building, image enhancement.
and top-ol-mind awareness are results
that can be measured. Again, you have
the challenge of linking expenditures to
these results, btit at least you can meas-
ure one component of the equation.
MHS: Are there reasons why ROI on
marketing might not be the ultimate
measure of marketing success in health-
care?
it depends on how you defme
ROI again. If you limit it to the first
definition (dollars gained for dollars
spent), it may be a frustrating exercise
with little to show at the end of the day.
If you broaden the discussion to say
ROI means a number of things (from
direct revenue generation to brand
building), then ROI becomes more
meaningful.
DM In healthcare, marketing
should be seen as more akin to public
relations than to the marketing that
characterizes consumer goods and
other more tangible products. It's hard
to measure the benefits of PR in dollars
and cents, and the same is true of
much healthcare marketing. However,
what may be even more important—
and less measurable—is the downside
of not implementing tbe marketing
campaign.
CM: Sometimes short-term ROI is a
bad measure of success. Building a
database of prospects who are potential
customers for your products requires
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knowing who your customers and
prospective customers are and then
delivering the right message to the right
person at the right time. Sometimes
that doesn't pay out in a single quarter
or even a single year. But, ultimately,
marketers who know who their cus-
tomers are and how to communicate
with them will be the winners over time,
ST: Given that most of the ROI
measurement assumptions don't hold
true in healthcare, traditional methods
for ROI measurement aren't particularly
relevant. Health professionals need to
determine what factors arc meaningful
to measure and then develop the sup-
port systems for measurmg them.
Ultimately, these are going to be more
global indicators than service-specific
measures.
MHS: Finally, what advice or direction
would you offer healthcare marketers
tr/ing to measure ROl?
First, decide what you want to
know and how you plan to use the
information. Measuring ROl for the sake
of measuring it isn't a good enough rea-
son. The additional knowledge should
be used to improve marketing efforts,
educate the organization, etc.
Engage senior management to deter-
mine their concept of ROl, marketing
effectiveness, and marketing invest-
ments. Also get them to specify what
the real tangible goals for marketing are
in their minds and what is it they
wani/need to accomplish from a busi-
ness perspective,
A lot of marketing plans are a laun-
dry list of everything the organization
can afford to do promotion wise—
instead of a targeted list of activities
matched up with specific business
objectives. The more aligned these are,
the easier it will be to measure market-
ing's impact.
Get in the habit ol building tracking
and measurement into every campaign
or marketing activity in the planning
stages before you actually implement.
Ask how the activity will be tracked,
what daia you mighi need to measure,
and what you'd do with the informa-
tion if you had it.
Look at other healthcare facilities
and note how they have measured cam-
paigns and maiketing efforts. This
information is available through trade
publications, associations, award pro-
grams, agencies and other consultants,
and your own network ol prolessionals.
Build ROl reviews into your calen-
dar so a couple of times a year you
carve out time specifically to discuss
marketing ROI with others in the
organization, thereby making it part ol
your priorities. Consider pay-for-per-
formance models where you have an
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incentive to achieve some measurable
goals for marketing,
DM: Marketers should measure ROI
for single, specific efforts and situations
where the measurement systems are rel-
atively good and are up to the chal-
lenge. We really need to think in terms
of "global" ROI (for the total organiza-
tion) in terms of awareness levels, pref-
erence levels, image ratings, market
share, referral volumes and sources,
and patient satisfaction—all important
measures of the healthcare brand. All oi
this should be thought through in
advance, and questions of how to track
results, what time period is reasonable,
whether to count indirect as well as
direct impact, e tc , should be addressed
on the front end,
CM: In the pharmaceutical industry
and much of healthcare, the investment
is relatively easy to measure. Us the
revenue that's hard to measure. It
becomes imperative to build in on the
front end the procedures for identifying
and quantifying revenue attributable to
the marketing effort. The closer one can
get to the individual consumer (who's
buying what and how much of it") the
better the ability to measure ROl, On-
line marketing holds great promise for
this approach,
•^  !: Organizations thai want to try to
measure marketing ROl should put sys-
tems into place to track the data need-
ed to calculate ROl, They should also
identify the market segments they want
to impact and develop means of track-
ing them.
It's also important to develop mecha-
nisms for isolating the results from mar-
keting efforts, whether in terms of dol-
lars or more subjective measures such as
image. Marketers should take a longitu-
dinal, meta-analysis approach that
allows the marketer to examine results
over a period of time, isolate confound-
ing variables, examine ROl from a mul-
tidimensional perspective, and coordi-
nate data collection efforts with other
departments and organizations, MHS
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